Telehealth firm Hims & Hers Health said on Monday it plans to sell Eli Lilly's diabetes and weight-loss drugs on its platform ...

Hims & Hers Health (NYSE:HIMS) stock gains as the company adds Eli Lilly's (LLY) weight loss therapy tirzepatide & generic ...

Is the era of sourcing cheaper weight loss drugs from the internet over? High demand for GLP-1 agonists — prescription drugs ...

The company’s stock rise reflects investor optimism following the news that Hims & Hers will provide both branded versions of ...

Hims shares gained as much as 14% in New York, their biggest gain since Feb. 19.

Shares of the health and wellness platform operator skyrocketed more than 670% between Jan. 1, 2024, and Feb. 19, 2025.

Hims & Hers Health (NYSE:HIMS) has taken investors on a wild ride in 2025. The stock surged nearly 200% earlier this year, ...

Eli Lilly (LLY) is taking legal action against makers of off-brand versions of its blockbuster diabetes and weight-loss drugs ...

Democratic Senator Maria Cantwell on Tuesday urged the Federal Aviation Administration to address critical concerns before ...

Explore what to expect now that the Hims & Hers stock price now that it has crashed hard in the past few weeks.

The company still expects to deliver strong revenue growth, though, and plans to market another weight-loss drug this year. Hims & Hers Health stock remains valued at a steep premium even after ...